Literature DB >> 12576371

Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response.

Carlos Agustí1, Ana Rañó, Xavier Filella, Juliá González, Asunción Moreno, Antoni Xaubet, Antoni Torres.   

Abstract

BACKGROUND: Glucocorticoid treatment alters immunoregulatory defense mechanisms and may therefore favor the development of different pulmonary infections.
METHODS: The etiology, prognostic factors, and associated inflammatory response of pulmonary infiltrates in 33 patients receiving long-term glucocorticoid treatment (LTGCT) were prospectively evaluated.
RESULTS: Aspergillus spp (n = 9, 31%) and Staphylococcus spp (n = 6, 21%) were the most common causative agents. Using different diagnostic techniques, we obtained a specific diagnosis in 28 of 33 episodes (85%) of pulmonary infiltrates. Bronchoscopic techniques provided the diagnosis in 64% of the cases. Crude mortality was 45%. Variables associated with mortality were as follows: age > 64 years, bilateral radiographic involvement, delay in diagnosis, inappropriate empirical treatment, Simplified Acute Physiology Score (SAPS) II > or = 25, and requirement for mechanical ventilation (MV). SAPS II > or = 25 (odds ratio [OR], 16; 95% confidence interval, 1 to 260) and MV requirement (OR, 50; 95% confidence interval, 2 to 360) were also significant on multivariate analysis. Pulmonary infections were associated with an increase in the concentration of relevant inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 both in serum and BAL. This local and systemic inflammatory response was attenuated when compared with the response observed in patients with pulmonary infections but without glucocorticoid treatment or receiving glucocorticoids for a short period of time (< 9 days).
CONCLUSIONS: Pulmonary infiltrates in patients receiving LTGCT are often caused by fungi and Gram-positive cocci, and are associated with attenuated local and systemic inflammatory response. Although in most cases, sputum cultures and bronchoscopic techniques are diagnostic, the associated mortality is high, particularly in those requiring MV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576371     DOI: 10.1378/chest.123.2.488

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

Review 1.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

2.  Invasive pulmonary aspergillosis due to Emericella nidulans var. echinulata, successfully cured by voriconazole and micafungin.

Authors:  Jin Yu; Xiangdong Mu; Ruoyu Li
Journal:  J Clin Microbiol       Date:  2013-01-30       Impact factor: 5.948

Review 3.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients.

Authors:  C Agustí; A Rañó; M Rovira; X Filella; N Benito; A Moreno; A Torres
Journal:  Thorax       Date:  2004-12       Impact factor: 9.139

5.  Clinical Features and Risk Factors of Severe Pneumonia in Children With Acute Lymphoblastic Leukemia.

Authors:  Chun-Yan Liu; Cheng Li
Journal:  Front Pediatr       Date:  2022-05-06       Impact factor: 3.569

6.  Twice daily fractionated dose administration of prednisolone compared to standard once daily administration to patients with glomerulonephritis or with kidney transplants.

Authors:  Sebastian Oliver Decker; Frieder Keller; Jens Mayer; Sylvia Stracke
Journal:  Med Klin (Munich)       Date:  2009-06-16

7.  Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients.

Authors:  Milica Popovic; Claudine A Blum; Nicole Nigro; Beat Mueller; Philipp Schuetz; Mirjam Christ-Crain
Journal:  Diabetologia       Date:  2016-09-10       Impact factor: 10.122

8.  Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials.

Authors:  Pradeesh Sivapalan; Jonas Rutishauser; Philipp Schüetz; Jens-Ulrik Jensen; Charlotte Suppli Ulrik; Jörg D Leuppi; Lars Pedersen; Beat Mueller; Josefin Eklöf; Tor Biering-Sørensen; Vibeke Gottlieb; Karin Armbruster; Julie Janner; Mia Moberg; Therese S Lapperre; Thyge L Nielsen; Andrea Browatzki; Alexander Mathioudakis; Jørgen Vestbo
Journal:  Respir Res       Date:  2021-05-21

9.  Expression of Toll-like receptor 4 in lungs of immune-suppressed rat with Acinetobacter baumannii infection.

Authors:  Yanmei Wang; Xiaohong Zhang; Xuanlin Feng; Xiaoshu Liu; Lei Deng; Zong-An Liang
Journal:  Exp Ther Med       Date:  2016-08-29       Impact factor: 2.447

10.  Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Kieren A Marr; Wendi M Lau; David P Facklam; Voravit Ratanatharathorn; Cornelia Becker; Andrew J Ullmann; Nita L Seibel; Patricia M Flynn; Jo-Anne H van Burik; Donald N Buell; Thomas F Patterson
Journal:  J Infect       Date:  2006-05-06       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.